<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>7
<FILENAME>form8kdawsonex992oct-15.txt
<DESCRIPTION>EXH. 99.2 - PRESS RELEASE 10-23-15
<TEXT>

                                  EXHIBIT 99.2




<PAGE>


CEL-SCI Corporation
May 22, 2015
Page 2

8229 Boone Boulevard, Suite 802                             COMPANY CONTACT:
Vienna, VA  22182.  USA                                     Gavin de Windt
Telephone (703) 506-9460                                    CEL-SCI Corporation
www.cel-sci.com                                             (703) 506-9460


             CEL-SCI PRICES PUBLIC OFFERING FOR UP TO $12 MILLION

Vienna, VA, October 23, 2015 - CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or
the "Company")  today  announced  that it has priced a best efforts  offering of
common  stock and warrants at a combined  price of $0.67 per unit of  securities
for aggregate gross proceeds of up to $12 million,  prior to deducting placement
agent  commissions  and offering  expenses.  Each unit  consists of one share of
common stock and one warrant to purchase one share of common  stock.  The common
stock and warrants  will  separate  immediately.  The  warrants are  immediately
exercisable, expire in five-years and have an exercise price of $0.67 per share.
This offering is expected to close on or about October 28, 2015,  subject to the
satisfaction of customary closing conditions.

CEL-SCI intends to use the net proceeds of the offering for its Phase 3 clinical
trial, an ongoing Phase 1 study in HIV/HPV co-infected patients,  other research
and development, and general and administrative expenses.

Dawson  James  Securities,  Inc. is acting as the sole  placement  agent for the
proposed offering on a best efforts basis.

A shelf registration  statement on Form S-3 declared effective by the Securities
and Exchange  Commission  ("SEC") on July 8, 2014, a prospectus  supplement  and
accompanying prospectus related to the offering have been filed with the SEC and
are available on the SEC's website located at  http://www.sec.gov.  The offering
may be  made  only  by  means  of the  prospectus  supplement  and  accompanying
prospectus,  copies of which may be obtained from Dawson James Securities, Inc.,
Attention:  Prospectus  Department,  1 North Federal  Highway,  5th Floor,  Boca
Raton, FL 33432, mmaclaren@dawsonjames.com or toll free at 866.928.0928.

This press release shall not constitute an offer to sell or the  solicitation of
an offer to buy any securities,  nor shall there be any sale of these securities
in any state or other  jurisdiction in which such offer,  solicitation,  or sale
would be unlawful prior to  registration or  qualification  under the securities
laws of such state or other jurisdiction.

Forward-Looking Statement

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans"  and  "expects"  and
similar  expressions  are  intended  to  identify  forward-looking   statements.
Forward-looking statements include, without limitation, the Company's ability to
complete  the  proposed  offering.  Such  statements  are  subject  to risks and
uncertainties  which could cause actual results to differ  materially from those
projected.  CEL-SCI  undertakes no obligation to publicly  release the result of
any revision to these forward-looking statements that may be made to reflect the
events or  circumstances  after the date hereof or to reflect the  occurrence of
unanticipated events.

</TEXT>
</DOCUMENT>
